Sort
89,613 grants matching “depression”
Brexpiprazole as an adjunctive treatment to buprenorphine to treat Opioid Use Disorder
$4,023,155Andy Forbes · Otsuka Pharmaceutical Development & Commercialization, Inc. · UG3 · FY2020 · DA
Dual-orexin antagonism as a mechanism for improving sleep and drug abstinence in opioid use disorder
$4,021,723Mark K. Greenwald · Wayne State University · U01 · FY2019 · HL
PET Radiopharmaceutical Sciences
$4,020,053Victor W Pike · National Institute Of Mental Health · ZIA · FY2016 · MH
Use of Continuous Glucose Monitoring with Automated Clinical Decision Support to Reduce Hypoglycemia in Older Adults with Type 1 Diabetes
$4,018,286Medha N Munshi · Joslin Diabetes Center · DP3 · FY2016 · DK
New, Rapidly-Acting Treatments for Treatment-Resistant Depression (RAPID)
$4,017,559Massachusetts General Hospital · N01 · FY2012 · MH
Healthy Aging In Neighborhoods of Diversity Across the Life Span (HANDLS)
$4,011,599Michele K Evans · National Institute On Aging · ZIA · FY2020 · AG
PET Radiopharmaceutical Sciences
$4,011,506Victor W Pike · National Institute Of Mental Health · ZIA · FY2010 · MH
MBRS-SCORE Program at UPR-Medical Sciences Campus
$4,010,603Walter I Silva · University Of Puerto Rico Med Sciences · S06 · FY2006 · GM
Bioanalysis, Drug Metabolism and New Drug Discovery
$4,004,627Josephine Egan · National Institute On Aging · ZIA · FY2024 · AG
Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose
$4,003,844Marco Pravetoni · University Of Washington · UH3 · FY2022 · DA
A Multi-Center Group to Study Acute Liver Failure in Children
$4,000,000Robert H Squires · University Of Pittsburgh At Pittsburgh · U01 · FY2014 · DK
CONSTRUCTION OF THE UNIVERSITY OF MICHIGAN DEPRESSION CENTER
$4,000,000University Of Michigan At Ann Arbor · C06 · FY2003 · RR
Border Biomedical Research Center
$3,992,246Robert Kirken · University Of Texas El Paso · U54 · FY2022 · MD
Development of SBS-226, a MOR agonist / DOR antagonist, for OUD
$3,984,629Jeffrey Reich · Sparian Biosciences, Inc. · UG3 · FY2025 · DA
Office of the Scientific Director
$3,970,691Susan Amara · National Institute Of Mental Health · ZIA · FY2018 · MH
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
$3,964,727Assiamira Ferrara · Kaiser Foundation Research Institute · UH3 · FY2020 · OD
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
$3,964,727Assiamira Ferrara · Kaiser Foundation Research Institute · UH3 · FY2021 · OD
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
$3,964,725Assiamira Ferrara · Kaiser Foundation Research Institute · UH3 · FY2022 · OD
NIMH Space Activation, Maintenance, and Improvement
$3,960,212Susan Amara · National Institute Of Mental Health · ZII · FY2021 · MH
Disease Status Drug Metabolism and New Drug Discovery
$3,957,647Irving William Wainer · National Institute On Aging · ZIA · FY2014 · AG
Development of SBS-226, a MOR agonist / DOR antagonist, for OUD
$3,957,359Jeffrey Reich · Sparian Biosciences, Inc. · UG3 · FY2024 · DA
Child and Family Development across the First Two Decades of Life
$3,951,931Marc H Bornstein · Child Health And Human Development · Z01 · FY2007 · HD
Development of (R,R)-dehydronorketamine for treatment resistant depression
$3,950,053Craig Thomas · National Center For Advancing Translational Sciences · ZIA · FY2022 · TR
Integrative Pathways to Health and Illness
$3,950,000University Of Wisconsin Madison · P01 · FY2002 · AG
Dissecting the Genomic Etiology of non-Mendelian Early-Onset Alzheimer Disease and Related Phenotypes
$3,944,132Gary Wayne Beecham · University Of Miami School Of Medicine · R01 · FY2020 · AG